- Home
- TBBK vs RCKT Comparison
TBBK vs RCKT Comparison
Compare TBBK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- RCKT
- Stock Information
- Founded
- TBBK 1999
- RCKT 1999
- Country
- TBBK United States
- RCKT United States
- Employees
- TBBK N/A
- RCKT N/A
- Industry
- TBBK Major Banks
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TBBK Finance
- RCKT Health Care
- Exchange
- TBBK Nasdaq
- RCKT Nasdaq
- Market Cap
- TBBK 2.7B
- RCKT 1.9B
- IPO Year
- TBBK 2004
- RCKT N/A
- Fundamental
- Price
- TBBK $50.51
- RCKT $17.13
- Analyst Decision
- TBBK Buy
- RCKT Strong Buy
- Analyst Count
- TBBK 3
- RCKT 9
- Target Price
- TBBK $55.00
- RCKT $53.22
- AVG Volume (30 Days)
- TBBK 564.7K
- RCKT 731.3K
- Earning Date
- TBBK 10-24-2024
- RCKT 11-04-2024
- Dividend Yield
- TBBK N/A
- RCKT N/A
- EPS Growth
- TBBK 16.52
- RCKT N/A
- EPS
- TBBK 3.95
- RCKT N/A
- Revenue
- TBBK $472,015,000.00
- RCKT N/A
- Revenue This Year
- TBBK N/A
- RCKT N/A
- Revenue Next Year
- TBBK $7.05
- RCKT $300.20
- P/E Ratio
- TBBK $12.71
- RCKT N/A
- Revenue Growth
- TBBK 6.71
- RCKT N/A
- 52 Week Low
- TBBK $29.92
- RCKT $15.98
- 52 Week High
- TBBK $59.26
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- TBBK 44.27
- RCKT 46.41
- Support Level
- TBBK $45.82
- RCKT $17.05
- Resistance Level
- TBBK $59.26
- RCKT $17.75
- Average True Range (ATR)
- TBBK 2.17
- RCKT 0.72
- MACD
- TBBK -0.96
- RCKT 0.06
- Stochastic Oscillator
- TBBK 35.86
- RCKT 40.23
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.